About QSAM Biosciences
QSAM Biosciences is a publicly listed company based in Palm Beach (United States) founded in 2004, and was acquired by Telix Pharma in February 2024. Developer of nuclear medicines for the treatment of bone cancer treatment bone marrow ablation. The company has 4 employees. Its chief executive, as recorded, is Kevin Bolin. Its focus areas include Life Sciences, Oncology, Drugs and Bone Cancer. Its legal entity is Q2EARTH INC. Its competitors include SpringWorks Therapeutics, Sana Biotechnology and Janux Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Nuclear medicines for treating bone cancer and bone marrow ablation are developed by QSAM Biosciences, founded in 2004 and based in Palm Beach, United States. Operations focus on radiopharmaceuticals like Samarium-153 DOTMP, known as CycloSam, which emits beta and gamma radiation to target cancer cells. Applications include osteosarcoma, metastatic bone cancers, immune and blood diseases, and sickle cell conditions within the biotechnology sector.
- Headquarters Palm Beach, United States
- Employees 4
- Stage Public
- SectorsHealthcare
- Website qsambio.com
- Social X Facebook
- Acquired by Telix Pharma (Feb 2024)
- Legal Name Q2earth Inc.
- Net Profit-$4.39 M (USD)20as on Dec 31, 2023
- EBITDA-$3.94 M (USD)28as on Dec 31, 2023
- Latest Funding Round$2.5M (USD), Post-IPO
Jan 2021
- InvestorsTelix Pharmaceuticals
& 1 more
- Employee Count4
- Acquired byTelix Pharma
(Feb 2024)
Funding Insights of QSAM Biosciences
- Total Rounds 3
- Last Round Post-IPO — $2.5M
- First Round $1M
(Mar 2017)
- Investors Count 1
All 3 funding rounds of QSAM Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $2.5M | Post-IPO | – | – | |
| Apr 2017 | $1M | Post-IPO | – | – | – |
| Mar 2017 | $1M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in QSAM Biosciences
QSAM Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Telix Pharmaceuticals and Checkmate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Checkmate Capital is backed by family office for private equity. | checkmatecapital.net | Beijing, China | ||
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy. | 2015 | telixpharma.com | Melbourne, Australia |
Investor details for QSAM Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of QSAM Biosciences
3 people are tracked at QSAM Biosciences (3 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Christopher Nelson | President | Leadership |
Kevin Bolin | CEO | Leadership |
Douglas R Baum | CEO | Leadership |
Complete people profiles for QSAM Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of QSAM Biosciences
5 dated milestones of QSAM Biosciences across 20 years, from founding to its latest funding, stage changes and deals.
- Founded QSAM Biosciences is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Post-IPO, of $2.5M.
- Exit Acquired by Telix Pharma.
- IPO Lists on the stock exchange (IPO).
Competitors of QSAM Biosciences
QSAM Biosciences has 3 listed competitors in our database, 3 of them funded. They include SpringWorks Therapeutics, Sana Biotechnology and Janux Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| springworkstx.com | 2017 | New York, United States | $229.6M | 305 | Small molecule therapeutics are developed for cancer and rare diseases. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| januxrx.com | 2017 | San Diego, United States | $181M | 59 | Immunotherapeutics for cancer treatment are developed to target solid tumors. |
Detailed competitors of QSAM Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as QSAM Biosciences (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qsam Biosciences
Complete news archive for QSAM Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QSAM Biosciences
QSAM Biosciences was founded in 2004 and raised its 1st funding round 13 years after it was founded.
QSAM Biosciences is headquartered in Palm Beach, United States. It is registered at Palm Beach, Florida, United States.
Kevin Bolin is the CEO of QSAM Biosciences, as recorded in our data.
QSAM Biosciences has 4 employees.
Nuclear medicines for treating bone cancer and bone marrow ablation are developed by QSAM Biosciences, founded in 2004 and based in Palm Beach, United States. Operations focus on radiopharmaceuticals like Samarium-153 DOTMP, known as CycloSam, which emits beta and gamma radiation to target cancer cells. Applications include osteosarcoma, metastatic bone cancers, immune and blood diseases, and sickle cell conditions within the biotechnology sector.
QSAM Biosciences's top competitors include SpringWorks Therapeutics, Janux Therapeutics and Sana Biotechnology.
QSAM Biosciences has 2 investors. Key investors include Telix Pharmaceuticals, and Checkmate Capital.
QSAM Biosciences operates through Q2earth Inc..
Yes. QSAM Biosciences was acquired by Telix Pharma in February 2024.